{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:13:05Z","timestamp":1791573185987,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone metastasis is a severe complication of advanced breast cancer, resulting in osteolysis and increased mortality in patients. Raddeanin A (RA), isolated from traditional Chinese herbs, is an oleanane-type triterpenoid saponin with anticancer potential. In this study, we investigated the effects of RA in breast cancer-induced osteolysis and elucidated the possible mechanisms involved in this process. We first verified that RA could suppress osteoclast formation and bone resorption in vitro. Next, we confirmed that RA suppressed Ti-particle-induced osteolysis in a mouse calvarial model, possibly through inhibition of the SRC\/AKT signaling pathway. A breast cancer-induced osteolysis mouse model further revealed the positive protective effects of RA by micro-computed tomography and histology. Finally, we demonstrated that RA inhibited invasion and AKT\/mammalian target of rapamycin signaling and induced apoptosis in MDA-MB-231 cells. These results indicate that RA is an effective inhibitor of breast cancer-induced osteolysis.<\/jats:p>","DOI":"10.1038\/s41419-018-0417-0","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T11:55:11Z","timestamp":1520423711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Qiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi\u2019ang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunwu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11418-009-0369-x","volume":"64","author":"L Fan","year":"2010","unstructured":"Fan, L. et al. Two new triterpenoid saponins from rhizome of Anemone raddeana Regel. J. Nat. Med. 64, 50\u201354 (2010).","journal-title":"J. Nat. Med."},{"key":"417_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.intimp.2008.03.021","volume":"8","author":"Y Sun","year":"2008","unstructured":"Sun, Y., Li, M. & Liu, J. Haemolytic activities and adjuvant effect of Anemone raddeana saponins (ARS) on the immune responses to ovalbumin in mice. Int. Immunopharmacol. 8, 1095\u20131102 (2008).","journal-title":"Int. Immunopharmacol."},{"key":"417_CR3","first-page":"910","volume":"27","author":"MK Wang","year":"2008","unstructured":"Wang, M.-K., Ding, L.-S. & Wu, F.-E. Antitumor effects of raddeanin A on S180, H22 and U14 cell xenografts in mice. Chin. J. Cancer 27, 910\u2013913 (2008).","journal-title":"Chin. J. Cancer"},{"key":"417_CR4","first-page":"813","volume":"66","author":"YX Sun","year":"2011","unstructured":"Sun, Y. X., Liu, J. C. & Liu, D. Y. Phytochemicals and bioactivities of Anemone raddeana Regel: a review. Pharmazie 66, 813\u2013821 (2011).","journal-title":"Pharmazie"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchromb.2013.01.019","volume":"923-924","author":"X Luan","year":"2013","unstructured":"Luan, X. et al. Determination of Raddeanin A in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J. Chromatogr. B 923-924, 43\u201347 (2013).","journal-title":"J. Chromatogr. B"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbrc.2013.08.060","volume":"439","author":"G Xue","year":"2013","unstructured":"Xue, G. et al. Raddeanin A induces human gastric cancer cells apoptosis and inhibits their invasion in vitro. Biochem. Biophys. Res. Commun. 439, 196\u2013202 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"417_CR7","first-page":"637","volume":"16","author":"Y Gao","year":"2010","unstructured":"Gao, Y. et al. Inhibitory effect of Raddeanin A in human non-small cell lung cancer H460 cells. Chin. J. Appl. Environ. Biol. 16, 637\u2013641 (2010).","journal-title":"Chin. J. Appl. Environ. Biol."},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2017.02.079","volume":"485","author":"JN Li","year":"2017","unstructured":"Li, J. N. et al. Synergy of Raddeanin A and cisplatin induced therapeutic effect enhancement in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 485, 335\u2013341 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.phymed.2014.11.008","volume":"22","author":"YY Guan","year":"2015","unstructured":"Guan, Y. Y. et al. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling. Phytomedicine Int. J. Phytother. Phytopharm. 22, 103\u2013110 (2015).","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"417_CR10","first-page":"9406758","volume":"2016","author":"YH Teng","year":"2016","unstructured":"Teng, Y. H. et al. Autophagy protects from Raddeanin A-induced apoptosis in SGC-7901 human gastric cancer cells. eCAM 2016, 9406758 (2016).","journal-title":"eCAM"},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman, R. E. & Rubens, R. D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55, 61\u201366 (1987).","journal-title":"Br. J. Cancer"},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen, Y. C., Sosnoski, D. M. & Mastro, A. M. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 12, 215 (2010).","journal-title":"Breast Cancer Res."},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2015.11.017","volume":"99","author":"M Futakuchi","year":"2016","unstructured":"Futakuchi, M., Fukamachi, K. & Suzui, M. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv. Drug Deliv. Rev. 99, 206\u2013211 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1677\/erc.1.00543","volume":"12","author":"GA Clines","year":"2005","unstructured":"Clines, G. A. & Guise, T. A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 12, 549\u2013583 (2005).","journal-title":"Endocr. Relat. Cancer"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/ijc.24263","volume":"124","author":"YC Kuo","year":"2009","unstructured":"Kuo, Y. C. et al. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int. J. Cancer 124, 2568\u20132576 (2009).","journal-title":"Int. J. Cancer"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132\u20135139 (2010).","journal-title":"J. Clin. Oncol."},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Van Poznak","year":"2011","unstructured":"Van Poznak, C. H. et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29, 1221\u20131227 (2011).","journal-title":"J. Clin. Oncol."},{"key":"417_CR18","first-page":"548","volume":"151","author":"E Kubista","year":"2001","unstructured":"Kubista, E. Breast cancer: figures and facts. Wien. Med. Wochenschr. 151, 548\u2013551 (2001).","journal-title":"Wien. Med. Wochenschr."},{"key":"417_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655\u20131664 (2004).","journal-title":"N. Engl. J. Med."},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10549-015-3290-x","volume":"149","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-kappaB signaling pathways. Breast Cancer Res. Treat. 149, 705\u2013714 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584\u2013593 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337\u2013342 (2003).","journal-title":"Nature"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/15216540500137669","volume":"57","author":"X Feng","year":"2005","unstructured":"Feng, X. RANKing intracellular signaling in osteoclasts. IUBMB Life 57, 389\u2013395 (2005).","journal-title":"IUBMB Life"},{"key":"417_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada, T., Nakashima, T., Hiroshi, N. & Penninger, J. M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17\u201325 (2006).","journal-title":"Trends Mol. Med."},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","volume":"7","author":"TJ de Vries","year":"2009","unstructured":"de Vries, T. J. et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol. Cancer Res. 7, 476\u2013488 (2009).","journal-title":"Mol. Cancer Res."},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1172\/JCI116032","volume":"90","author":"BF Boyce","year":"1992","unstructured":"Boyce, B. F., Yoneda, T., Lowe, C., Soriano, P. & Mundy, G. R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90, 1622\u20131627 (1992).","journal-title":"J. Clin. Invest."},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1002\/jcb.23170","volume":"112","author":"S Dai","year":"2011","unstructured":"Dai, S., Abu-Amer, W., Karuppaiah, K. & Abu-Amer, Y. Evidence that the kinase-truncated c-Src regulates NF-kappaB signaling by targeting NEMO. J. Cell. Biochem. 112, 2463\u20132470 (2011).","journal-title":"J. Cell. Biochem."},{"key":"417_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S1097-2765(00)80232-4","volume":"4","author":"BR Wong","year":"1999","unstructured":"Wong, B. R. et al. TRANCE, a TNF family member, activates Akt\/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041\u20131049 (1999).","journal-title":"Mol. Cell"},{"key":"417_CR29","doi-asserted-by":"publisher","first-page":"30011","DOI":"10.1074\/jbc.M100414200","volume":"276","author":"JR Arron","year":"2001","unstructured":"Arron, J. R. et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J. Biol. Chem. 276, 30011\u201330017 (2001).","journal-title":"J. Biol. Chem."},{"key":"417_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1101\/gad.840301","volume":"15","author":"L Xing","year":"2001","unstructured":"Xing, L. et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. 15, 241\u2013253 (2001).","journal-title":"Genes Dev."},{"key":"417_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.biochem.70.1.535","volume":"70","author":"B Vanhaesebroeck","year":"2001","unstructured":"Vanhaesebroeck, B. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535\u2013602 (2001).","journal-title":"Annu. Rev. Biochem."},{"key":"417_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccr.2011.05.020","volume":"19","author":"B Beagle","year":"2011","unstructured":"Beagle, B. & Fruman, D. A. A lipid kinase cousin cooperates to promote cancer. Cancer Cell 19, 693\u2013695 (2011).","journal-title":"Cancer Cell"},{"key":"417_CR33","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20121571","volume":"210","author":"A Soler","year":"2013","unstructured":"Soler, A. et al. Inhibition of the p110alpha isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J. Exp. Med. 210, 1937\u20131945 (2013).","journal-title":"J. Exp. Med."},{"key":"417_CR34","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/onc.2013.265","volume":"33","author":"E Hirsch","year":"2014","unstructured":"Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A. & Martini, M. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 33, 3083\u20133090 (2014).","journal-title":"Oncogene"},{"key":"417_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.11.013","volume":"158","author":"FJ Carmona","year":"2016","unstructured":"Carmona, F. J. et al. AKT signaling in ERBB2-amplified breast cancer. Pharmacol. Ther. 158, 63\u201370 (2016).","journal-title":"Pharmacol. Ther."},{"key":"417_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"417_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nm.4076","volume":"22","author":"J Luo","year":"2016","unstructured":"Luo, J. et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 22, 539\u2013546 (2016).","journal-title":"Nat. Med."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0417-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:48:52Z","timestamp":1671536932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0417-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"2 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"376"}}